Skip to content

Revolution Medicines

US · RVMD #499 by market cap Listed 2020
161.20 +1.77 +1.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 14.52 Expensive vs history 87th percentile
5-year average 6.28 · #482 of 511 in Biotechnology
P/E ratio -17.66 Cheap vs history 15th percentile
5-year average -11.60 · forward -84.56
P/S ratio 176.49 In line with history 43rd percentile
5-year average 10,658.18 · forward 16.36 · #321 of 392 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Revolution Medicines (RVMD) 34.87B -17.66 14.52 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value176.51 Economic moatNone UncertaintyHigh

Trading 9.5% below Morningstar's fair value estimate.

Fair value

Revolution Medicines Inc is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 10% discount to our quantitative fair value estimate of $176.51 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's balance sheet strengthens our estimated valuation. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 8.4 ranks in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are undervalued.

On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 0.6%, for example, ranks in the bottom 10% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.

Revolution Medicines discussion 0 comments

Add a comment